| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | ||
| Market Cap | 104.36 Cr. | |
| Enterprise Value(EV) | 105.48 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.22 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 26.37 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 31.70 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 2.91 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 2.00 | Calculated using Price: 5.83 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 17.90 Cr. | 179,009,534 Shares |
| FaceValue | 1 | |
| Company Profile | ||
| Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements. | ||
| 1 Day |
|
+1.91% |
| 1 Week |
|
+3.90% |
| 1 Month |
|
+14.01% |
| 3 Month |
|
-14.20% |
| 6 Month |
|
-12.93% |
| 1 Year |
|
-23.50% |
| 2 Year |
|
+57.53% |
| 5 Year |
|
+58.81% |
| 10 Year |
|
+463.46% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 0.82 | 2.57 | 8.69 | 9.14 | 2.67 | 6.75 | 5.32 | 10.66 | 9.35 | |
| Return on Capital Employed (%) | 3.63 | 4.57 | 11.78 | 11.61 | 6.31 | 10.49 | 8.32 | 13.18 | 11.78 | |
| Return on Assets (%) | 0.54 | 1.66 | 5.77 | 5.94 | 1.68 | 4.34 | 3.40 | 6.95 | 6.16 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 25 | 26 | 28 | 31 | 32 | 34 | 36 | 40 | 44 | 46 | |
| Non Curr. Liab. | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | ||
| Curr. Liab. | 12 | 13 | 12 | 17 | 18 | 17 | 21 | 19 | 24 | 18 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 74 | |
| Non Curr. Assets | 23 | 22 | 23 | 23 | 23 | 23 | 22 | 23 | 22 | 22 | |
| Curr. Assets | 16 | 17 | 19 | 26 | 28 | 29 | 35 | 36 | 47 | 52 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 74 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 35 | 32 | 39 | 42 | 44 | 56 | 56 | 60 | 61 | 68 | |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Total Income | 35 | 32 | 39 | 42 | 45 | 57 | 57 | 60 | 63 | 70 | |
| Total Expenditure | -33 | -30 | -34 | -37 | -42 | -52 | -52 | -53 | -56 | -63 | |
| PBIDT | 2 | 2 | 4 | 5 | 3 | 5 | 4 | 7 | 7 | 7 | |
| Interest | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Exceptional Items | 0 | 0 | 0 | 0 | |||||||
| PAT | 0 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 4 | 4 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 0 | 0 | 3 | 0 | 3 | 2 | -2 | -1 | 7 | |
| Cash Fr. Inv. | -1 | -1 | 0 | -1 | -1 | -1 | -1 | 0 | 0 | -1 | |
| Cash Fr. Finan. | 0 | 0 | 0 | -2 | 1 | -2 | 1 | 0 | 2 | 2 | |
| Net Change | -2 | 0 | 0 | 0 | 0 | 0 | 2 | -2 | 0 | 7 | |
| Cash & Cash Eqvt | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 8 |
|
Mon, 20 Mar 2023
Approval From The Factories Department Of Andhra Pradesh For The Change In The Name Of Factory And Occupier In Favour Of Deccan Remedies Limited Go through the enclosed Announcement |
|
Thu, 02 Mar 2023
Announcement under Regulation 30 (LODR)-Acquisition Pursuant to announcement of Board Meeting dated January 04 2022 we hereby inform you 836 165 equity shares equivalent to 6.73% of Deccan Remedies Limited (DRL) acquired from the existing promoters shareholders group and the share funded through internal accruals and in turn the Company will hold 51% equity shares of DRL.Further the Company holds composition of the Board Directors and referring to the above share acquired exercises or controls more than one-half of the total voting power either at its own or together with one or more of its promoters shareholders group. Based on controlling position and voting power in DRL the Company will fall under Sec.2(46) of the Companies Act (CA) 2013 Holding Company definition and DRL shall fall Subsidiary Company Definition u/Sec.2(87) of the CA 2013. |
|
Thu, 02 Mar 2023
Deccan Remedies Limited Acquired Pharma Unit Located JN Pharma City Visakhapatnam Pursuant to concord entered between DRL and M/s. Forel Labs Private Limited (FLPL) DRL acquired live running US FDA (Food and Drug Administration) complied plant of FLPL located at Plot #58A Road #1 J.N.Pharma City Parawada Visakhapatnam - 531 021 AP India which have capacity of 90 KL and licence to run various API registration for the above manufacturing plant is completed and approved by the SRO Lankelapalem Visakhapatnam. |
| Tue, 21 Mar 2023 |
High Delivery Percentage
|
Opening at Low
|
Closing Above Previous High
|
High Increase in 1 Month
|
High Increase in 2 Years
|
Equities
M.F.
Sectors